In Patients with Advanced Ovarian Cancer, Olaparib/Bevacizumab as First-Line Maintenance Reduced the Risk of Progression or Death
Combination treatment is even more effective in women with ovarian cancer with BRCA mutations or homologous recombination deficiency (HRD)-positive tumors.
Are patient-reported outcomes (PROs) similar in the placebo and the niraparib groups, suggesting that over the course of treatment niraparib does not adversely affect patients’ quality of life? Results of the PRIMA/ENGOT-OV26/GOG-3012 trial begin to elucidate the answer to this question.
The combination of lenvatinib + pembrolizumab exhibited a manageable safety profile and encouraging efficacy in patients with heavily pretreated ovarian cancer, as well as those with a previous history of treatment failure.
Phase 3 Trial of Tumor Treating Fields and Concomitant Weekly Paclitaxel for the Treatment of Platinum-Resistant Ovarian Cancer
The phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 study is exploring the use of an antimitotic therapy tumor treating (TT) fields plus weekly paclitaxel in patients with platinum-resistant ovarian cancer.
Assessing Olaparib Combined with Pegylated Liposomal Doxorubicin for Treatment of Platinum-Resistant Ovarian Cancer
In this study, researchers explored whether there is a potential synergistic effect of olaparib when combined with pegylated liposomal doxorubicin, highlighting a potential means to improve tolerability.
Efficacy of Niraparib in Potentially Difficult-to-Treat Patients with Newly Diagnosed Ovarian Cancer Based on BRCAwt Status
When utilized as maintenance therapy after frontline treatment of ovarian cancer in patients with BRCAwt tumors, niraparib improved progression-free survival (PFS), even in the most difficult-to-treat patients.
In Women with Platinum-Sensitive Ovarian Cancer, There Was No Difference in PFS Between Platinum-Based Chemotherapy and Olaparib plus Cediranib
Results from a previous study indicated that treatment with the combination would lead to improvement in progression-free survival (PFS) compared with treatment with olaparib alone.
Impact of Visible Residual Disease, Other Risk Factors on Advanced Ovarian Cancer Progression and Death: Real-World Evidence
This real-world study based primarily on community-based practice data showed that a key predictor of time to next treatment and mortality in patients with advanced ovarian cancer was visible residual disease.
Patient-reported outcomes from the phase 3 PRIMA clinical trial showed no detrimental effect of niraparib on quality-of-life measures compared with placebo in patients with newly diagnosed ovarian cancer.
Information on clinical aspects of COVID-19 and social and financial support services for the cancer community are abundant.